Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Heisig, Anne, Sörensen, Jan, Zimmermann, Stefanie-Yvonne, Schöning, Stefan, Schwabe, Dirk, Kvasnicka, Hans-Michael, Schwentner, Raphaela, Hutter, Caroline, Lehrnbecher, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://ncbi.nlm.nih.gov/pubmed/29774135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25277
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados